How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy - PubMed (original) (raw)
How antidepressant drugs act: A primer on neuroplasticity as the eventual mediator of antidepressant efficacy
Chittaranjan Andrade et al. Indian J Psychiatry. 2010 Oct.
Abstract
Depression is conventionally viewed as a state of chemical imbalance, and antidepressants are suggested to act through increasing monoaminergic neurotransmission. These views are currently considered simplistic. This article examines the animal and human literature on the neurohistological mechanisms underlying stress, depression and antidepressant treatment. Pathological stress and depression are associated with changes such as loss of dendritic spines, shrinkage of the dendritic tree and loss of synapses in the hippocampus and prefrontal cortex. There is also a decrease in glia. Apoptosis may occur under extreme circumstances. In contrast, there is increased dendritic arborization and synaptogenesis in the amygdala. Antidepressant treatment protects against and even reverses some but not all of these stress-induced neurohistological changes. Pathological stress results in an aberrant neuroplasticity response characterized by abnormally increased activity in the amygdala and by impaired functioning of the hippocampus, prefrontal cortex and downstream structures. This aberrant neuroplasticity response directly explains most of the clinical symptoms of depression. Antidepressant treatment protects against stress-induced pathoplastic neurohistological and neurocognitive changes. Antidepressant treatment also restores functional neuroplasticity in stressed organisms and, thereby, presumably, facilitates re-adaptation through learning and memory mechanisms. Thus, the stress-depression syndrome and the therapeutic and prophylactic efficacy of antidepressant treatments can be explained through a hardwiring analogy. In this context, glutamate is an important neurotransmitter.
Keywords: Depression; amygdala; antidepressant drugs; electroconvulsive therapy; hippocampus; mechanism of action; neuroplasticity; prefrontal cortex; stress.
Conflict of interest statement
Conflict of Interest: None declared
Similar articles
- Neuroplasticity and major depression, the role of modern antidepressant drugs.
Serafini G. Serafini G. World J Psychiatry. 2012 Jun 22;2(3):49-57. doi: 10.5498/wjp.v2.i3.49. World J Psychiatry. 2012. PMID: 24175168 Free PMC article. Review. - Neurobiological and clinical effects of the antidepressant tianeptine.
Kasper S, McEwen BS. Kasper S, et al. CNS Drugs. 2008;22(1):15-26. doi: 10.2165/00023210-200822010-00002. CNS Drugs. 2008. PMID: 18072812 Review. - The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs.
Quesseveur G, Gardier AM, Guiard BP. Quesseveur G, et al. Curr Drug Targets. 2013 Oct;14(11):1277-94. doi: 10.2174/13894501113149990209. Curr Drug Targets. 2013. PMID: 24020973 Review. - Neuroplasticity-related mechanisms underlying the antidepressant-like effects of traditional herbal medicines.
Hirshler Y, Doron R. Hirshler Y, et al. Eur Neuropsychopharmacol. 2017 Oct;27(10):945-958. doi: 10.1016/j.euroneuro.2017.07.008. Epub 2017 Aug 12. Eur Neuropsychopharmacol. 2017. PMID: 28807619 Review. - [Depression and treatment. Apoptosis, neuroplasticity and antidepressants].
Arantes-Gonçalves F, Coelho R. Arantes-Gonçalves F, et al. Acta Med Port. 2006 Jan-Feb;19(1):9-20. Epub 2006 Apr 30. Acta Med Port. 2006. PMID: 16987439 Review. Portuguese.
Cited by
- Psychopharmacological Approaches for Neural Plasticity and Neurogenesis in Major Depressive Disorders.
Matar D, Serhan A, El Bilani S, Faraj RA, Hadi BA, Fakhoury M. Matar D, et al. Adv Exp Med Biol. 2024;1456:27-48. doi: 10.1007/978-981-97-4402-2_2. Adv Exp Med Biol. 2024. PMID: 39261422 Review. - Evaluation of anti-depressant and anxiolytic activity of Rasayana Ghana Tablet (A compound Ayurvedic formulation) in albino mice.
Deole YS, Chavan SS, Ashok BK, Ravishankar B, Thakar AB, Chandola HM. Deole YS, et al. Ayu. 2011 Jul;32(3):375-9. doi: 10.4103/0974-8520.93918. Ayu. 2011. PMID: 22529654 Free PMC article. - Searching for the mechanism(s) of ECT's therapeutic effect.
McCall WV, Andrade C, Sienaert P. McCall WV, et al. J ECT. 2014 Jun;30(2):87-9. doi: 10.1097/YCT.0000000000000121. J ECT. 2014. PMID: 24755719 Free PMC article. - From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder.
Liu B, Liu J, Wang M, Zhang Y, Li L. Liu B, et al. Front Cell Neurosci. 2017 Sep 28;11:305. doi: 10.3389/fncel.2017.00305. eCollection 2017. Front Cell Neurosci. 2017. PMID: 29033793 Free PMC article. Review. - Intramuscular ketamine in acute depression: A report on two cases.
Harihar C, Dasari P, Srinivas JS. Harihar C, et al. Indian J Psychiatry. 2013 Apr;55(2):186-8. doi: 10.4103/0019-5545.111461. Indian J Psychiatry. 2013. PMID: 23825857 Free PMC article.
References
- Andrade C. Psychopharmacology. In: Bhugra D, Ranjith G, Chaturvedi SK, editors. Handbook of Psychiatry: A South Asian Perspective. 2010. New Delhi:: Byword Viva; 2nd. in press.
- Duman RS. Introduction: Theories of depression - from monoamines to neuroplasticity. In: Olie JP, Costa e Silve JA, Macher JP, editors. Neuroplasticity: A New Approach to the Pathophysiology of Depression. London: Science Press Ltd; 2004. pp. 1–11.
- Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacol Rev. 2008;33:88–109. - PubMed
- Fuchs E. Animal models of depression. In: Olie JP, Costa e Silve JA, Macher JP, editors. Neuroplasticity: A New Approach to the Pathophysiology of Depression. London: Science Press Ltd; 2004. pp. 39–50.
- Sousa N, Almeida OF. Corticosteroids: Sculptors of the hippocampal formation. Rev Neurosci. 2002;13:59–84. - PubMed